glp 1 and prostate cancer Glucagon-like peptide receptor agonists risk: advancing precision medicine through mechanistic understanding and clinical evidence | Biomarker Research May Patients Receiving GLP-1 Agonists

When combined with tirzepatide, it may help boost the bodys ability to use fat and glucose efficiently, complementing the metabolic effects of tirzepatide

demonstrated that liraglutide reduced thigh MFI by 7.8%, suggesting an improvement in muscle composition [48]

Further dose increases: After at least 4 weeks on the current dose, the dosage may be increased in 2.5 mg increments

Both medications are TGA approved for the treatment of heart failure with preserved ejection fraction (HFpEF), but at the time of writing, neither is PBS subsidised for this indication (refer to the PBS schedule and TGA website for full details)